Abstract：
UNASSIGNED: Cervical screening programmes differ in the age of women recommended for primary human papillomavirus (HPV) testing. This study aims to determine the clinical efficacy and impact of 14-high-risk HPV DNA testing for women from 25 years old.
UNASSIGNED: This was a retrospective analysis of data collected prospectively from women 25 years or older who attended hospital-based gynaecology clinics for cervical screening. Women with history of cervical neoplasia or abnormal cytology were excluded. High-risk HPV DNA testing with partial genotyping for HPV-16 and HPV-18 were performed on cobas 4800 System (Roche Diagnostics International AG, Rotkreuz, Switzerland). Women tested positive for the 12 other high-risk HPV subtypes (HPV-12 other) had a reflex cytology test. Positive screening included positive for HPV-16 and/or HPV-18, HPV-12 other with cytology abnormalities equal to or greater than atypical squamous cells of undetermined significance, and repeated positive HPV at 12 months. HPV detection and colposcopy referral rates, and detection of high-grade neoplasia were determined.
UNASSIGNED: Of 10,967 women studied, 822 (7.50%) were HPV DNA positive. The overall discharge rate to routine screening according to screening protocol was 93.1%. Colposcopy referral rate was 4.4%. The screening detected 41 cervical intraepithelial neoplasia grade 2+ (CIN2+) (0.37%) and 31 (0.28%) CIN3+. The number of colposcopies needed per case of CIN2+ was 9.5, similar for women below and above 30 years old. The number of colposcopies needed per case of CIN3+ for HPV-16 positivity was 8.5, compared to 17.0 for other categories (P=0.040). Colposcopy efficacy was similar for HPV-18 and HPV-12 other positivity with abnormal cytology.
UNASSIGNED: Taking CIN2+ detection and colposcopy referral rate as endpoints, HPV testing in Singapore can be extended to include women from 25 years old.
UNASSIGNED: This was a retrospective analysis of data collected prospectively from women 25 years or older who attended hospital-based gynaecology clinics for cervical screening. Women with history of cervical neoplasia or abnormal cytology were excluded. High-risk HPV DNA testing with partial genotyping for HPV-16 and HPV-18 were performed on cobas 4800 System (Roche Diagnostics International AG, Rotkreuz, Switzerland). Women tested positive for the 12 other high-risk HPV subtypes (HPV-12 other) had a reflex cytology test. Positive screening included positive for HPV-16 and/or HPV-18, HPV-12 other with cytology abnormalities equal to or greater than atypical squamous cells of undetermined significance, and repeated positive HPV at 12 months. HPV detection and colposcopy referral rates, and detection of high-grade neoplasia were determined.
UNASSIGNED: Of 10,967 women studied, 822 (7.50%) were HPV DNA positive. The overall discharge rate to routine screening according to screening protocol was 93.1%. Colposcopy referral rate was 4.4%. The screening detected 41 cervical intraepithelial neoplasia grade 2+ (CIN2+) (0.37%) and 31 (0.28%) CIN3+. The number of colposcopies needed per case of CIN2+ was 9.5, similar for women below and above 30 years old. The number of colposcopies needed per case of CIN3+ for HPV-16 positivity was 8.5, compared to 17.0 for other categories (P=0.040). Colposcopy efficacy was similar for HPV-18 and HPV-12 other positivity with abnormal cytology.
UNASSIGNED: Taking CIN2+ detection and colposcopy referral rate as endpoints, HPV testing in Singapore can be extended to include women from 25 years old.
摘要：
宫颈筛查计划因推荐用于原发性人乳头瘤病毒（HPV）检测的女性年龄而异。这项研究旨在确定14高危HPVDNA检测对25岁以上女性的临床疗效和影响。
这是一项回顾性分析，对在医院妇科诊所就诊的25岁或以上妇女进行宫颈筛查的前瞻性数据进行了回顾性分析。排除有宫颈瘤变史或细胞学异常的女性。在cobas4800系统上进行了高危型HPVDNA检测，并对HPV-16和HPV-18进行了部分基因分型（RocheDiagnosticsInternationalAG，Rotkreuz,瑞士)。其他12种高风险HPV亚型（HPV-12其他）检测呈阳性的女性进行了反射细胞学检查。阳性筛查包括HPV-16和/或HPV-18、HPV-12阳性，其他细胞学异常等于或大于不确定意义的非典型鳞状细胞。并在12个月时重复HPV阳性。HPV检测和阴道镜转诊率，并确定了高级别肿瘤的检测。
■研究了10967名女性，822例（7.50%）HPVDNA阳性。根据筛查方案进行常规筛查的总出院率为93.1％。阴道镜转诊率为4.4%。筛查共检出宫颈上皮内瘤变2级+(CIN2+)41例(0.37%)和CIN3+31例(0.28%)。每例CIN2+病例所需的阴道镜检查数为9.5，30岁以下和30岁以上的女性相似。对于HPV-16阳性，每例CIN3+所需的阴道镜复制数量为8.5，而其他类别为17.0（P=0.040）。HPV-18和HPV-12其他阳性的阴道镜疗效相似，细胞学异常。
■以CIN2+检测和阴道镜转诊率作为终点，新加坡的HPV检测可以扩展到25岁以上的女性。
这是一项回顾性分析，对在医院妇科诊所就诊的25岁或以上妇女进行宫颈筛查的前瞻性数据进行了回顾性分析。排除有宫颈瘤变史或细胞学异常的女性。在cobas4800系统上进行了高危型HPVDNA检测，并对HPV-16和HPV-18进行了部分基因分型（RocheDiagnosticsInternationalAG，Rotkreuz,瑞士)。其他12种高风险HPV亚型（HPV-12其他）检测呈阳性的女性进行了反射细胞学检查。阳性筛查包括HPV-16和/或HPV-18、HPV-12阳性，其他细胞学异常等于或大于不确定意义的非典型鳞状细胞。并在12个月时重复HPV阳性。HPV检测和阴道镜转诊率，并确定了高级别肿瘤的检测。
■研究了10967名女性，822例（7.50%）HPVDNA阳性。根据筛查方案进行常规筛查的总出院率为93.1％。阴道镜转诊率为4.4%。筛查共检出宫颈上皮内瘤变2级+(CIN2+)41例(0.37%)和CIN3+31例(0.28%)。每例CIN2+病例所需的阴道镜检查数为9.5，30岁以下和30岁以上的女性相似。对于HPV-16阳性，每例CIN3+所需的阴道镜复制数量为8.5，而其他类别为17.0（P=0.040）。HPV-18和HPV-12其他阳性的阴道镜疗效相似，细胞学异常。
■以CIN2+检测和阴道镜转诊率作为终点，新加坡的HPV检测可以扩展到25岁以上的女性。
